Role of arsenic (+3 oxidation state) methyltransferase in arsenic metabolism and toxicity

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 1870-1875

  Sumi, Daigo ^a   Himeno, Seiichiro ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Alternative splicing; Arsenic; Arsenite (+3 oxidation state) methyltransferase; Methylation; Polymorphism

Indexed keywords

ARSENIC; ARSENIC METHYLTRANSFERASE; ARSENIC TRIOXIDE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO ACID SUBSTITUTION; ARSENIC POISONING; CATALYSIS; CYTOTOXICITY; DETOXIFICATION; EXON; GENE SILENCING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INTRON; METAL METABOLISM; METHYLATION; NONHUMAN; OXIDATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ALTERNATIVE SPLICING; ANIMALS; ARSENIC; ENVIRONMENTAL POLLUTANTS; HUMANS; METHYLTRANSFERASES; POLYMORPHISM, GENETIC;

EID: 84869209063     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b212015     Document Type: Review

References (52)

1. Nordstrom DK. Public health. Worldwide occurrences of arsenic in ground water. Science, 296, 2143-2145 (2002).
2. Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl. Cancer Inst., 40, 453-463 (1968).
3. Lagerkvist BE, Linderholm H, Nordberg GF. Arsenic and Raynaud's phenomenon. Vasospastic tendency and excretion of arsenic in smelter workers before and after the summer vacation. Int. Arch. Occup. Environ. Health, 60, 361-364 (1988).
4. Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. Vascular effects of chronic arsenic exposure: a review. Epidemiol. Rev., 16, 184-209 (1994).
5. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, Kuo TL, Tai TY. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension, 25, 53-60 (1995).
6. Kadono T, Inaoka T, Murayama N, Ushijima K, Nagano M, Nakamura S, Watanabe C, Tamaki K, Ohtsuka R. Skin manifestations of arsenicosis in two villages in Bangladesh. Int. J. Dermatol., 41, 841-846 (2002).
7. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 88, 1052-1061 (1996).
8. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 89, 3345-3353 (1997).
9. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339, 1341-1348 (1998).
10. Crecelius EA. Changes in the chemical speciation of arsenic following ingestion by man. Environ. Health Perspect., 19, 147-150 (1977).
11. Zakharyan RA, Tsaprailis G, Chowdhury UK, Hernandez A, Aposhian HV. Interactions of sodium selenite, glutathione, arsenic species, and omega class human glutathione transferase. Chem. Res. Toxicol., 18, 1287-1295 (2005).
12. Radabaugh TR, Sampayo-Reyes A, Zakharyan RA, Aposhian HV. Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem. Res. Toxicol., 15, 692-698 (2002).
13. Németi B, Regonesi ME, Tortora P, Gregus Z. Polynucleotide phosphorylase and mitochondrial ATP synthase mediate reduction of arsenate to the more toxic arsenite by forming arsenylated analogues of ADP and ATP. Toxicol. Sci., 117, 270-281 (2010).
14. Lin S, Shi Q, Nix FB, Styblo M, Beck MA, Herbin-Davis KM, Hall LL, Simeonsson JB, Thomas DJ. A novel S-adenosyl-L-methionine:arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem., 277, 10795-10803 (2002).
15. Aposhian HV, Aposhian MM. Arsenic toxicology: five questions. Chem. Res. Toxicol., 19, 1-15 (2006).
16. Healy SM, Wildfang E, Zakharyan RA, Aposhian HV. Diversity of inorganic arsenite biotransformation. Biol. Trace Elem. Res., 68, 249-266 (1999).
17. Waters SB, Devesa V, Del Razo LM, Styblo M, Thomas DJ. Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Chem. Res. Toxicol., 17, 404-409 (2004).
18. Hayakawa T, Kobayashi Y, Cui X, Hirano S. A new metabolic pathway of arsenite:arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch. Toxicol., 79, 183-191 (2005).
19. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol., 74, 289-299 (2000).
20. Hirano S, Kobayashi Y. Cytotoxic effects of S-(dimethylarsino)- glutathione: a putative intermediate metabolite of inorganic arsenicals. Toxicology, 227, 45-52 (2006).
21. Sakurai T, Kojima C, Kobayashi Y, Hirano S, Sakurai MH, Waalkes MP, Himeno S. Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215). Br. J. Pharmacol., 149, 888-897 (2006).
22. Kumagai Y, Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu. Rev. Pharmacol. Toxicol., 47, 243-262 (2007).
23. Drobna Z, Xing W, Thomas DJ, Stýblo M. shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells. Chem. Res. Toxicol., 19, 894-898 (2006).
24. Ren X, Aleshin M, Jo WJ, Dills R, Kalman DA, Vulpe CD, Smith MT, Zhang L. Involvement of N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) in arsenic biomethylation and its role in arsenic-induced toxicity. Environ. Health Perspect., 119, 771-777 (2011).
25. Drobná Z, Waters SB, Devesa V, Harmon AW, Thomas DJ, Stýblo M. Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase. Toxicol. Appl. Pharmacol., 207, 147-159 (2005).
26. Song X, Geng Z, Li X, Hu X, Bian N, Zhang X, Wang Z. New insights into the mechanism of arsenite methylation with the recombinant human arsenic (+3) methyltransferase (hAS3MT). Biochimie, 92, 1397-1406 (2010).
27. Drobna Z, Naranmandura H, Kubachka KM, Edwards BC, Herbin-Davis K, Styblo M, Le XC, Creed JT, Maeda N, Hughes MF, Thomas DJ. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem. Res. Toxicol., 22, 1713-1720 (2009).
28. Yokohira M, Arnold LL, Pennington KL, Suzuki S, Kakiuchi-Kiyota S, Herbin-Davis K, Thomas DJ, Cohen SM. Severe systemic toxicity and urinary bladder cytotoxicity and regenerative hyperplasia induced by arsenite in arsenic (+3 oxidation state) methyltransferase knockout mice. A preliminary report. Toxicol. Appl. Pharmacol., 246, 1-7 (2010).
29. Yokohira M, Arnold LL, Pennington KL, Suzuki S, Kakiuchi-Kiyota S, Herbin-Davis K, Thomas DJ, Cohen SM. Effect of sodium arsenite dose administered in the drinking water on the urinary bladder epithelium of female arsenic (+3 oxidation state) methyltransferase knockout mice. Toxicol. Sci., 121, 257-266 (2011).
30. Concha G, Nermell B, Vahter MV. Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina. Environ. Health Perspect., 106, 355-359 (1998).
31. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, Lue LC, Chen GS, Chen CJ. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol. Biomarkers Prev., 6, 589-596 (1997).
32. Lindberg AL, Rahman M, Persson LA, Vahter M. The risk of arsenic induced skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the age at first exposure. Toxicol. Appl. Pharmacol., 230, 9-16 (2008).
33. Yu RC, Hsu KH, Chen CJ, Froines JR. Arsenic methylation capacity and skin cancer. Cancer Epidemiol. Biomarkers Prev., 9, 1259-1262 (2000).
34. Del Razo LM, García-Vargas GG, Vargas H, Albores A, Gonsebatt ME, Montero R, Ostrosky-Wegman P, Kelsh M, Cebrián ME. Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Arch. Toxicol., 71, 211-217 (1997).
35. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol. Lett., 112-113, 209-217 (2000).
36. Drobná Z, Waters SB, Walton FS, LeCluyse EL, Thomas DJ, Stýblo M. Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes. Toxicol. Appl. Pharmacol., 201, 166-177 (2004).
37. Meza MM, Yu L, Rodriguez YY, Guild M, Thompson D, Gandolfi AJ, Klimecki WT. Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children. Environ. Health Perspect., 113, 775-781 (2005).
38. Schläwicke Engström K, Broberg K, Concha G, Nermell B, Warholm M, Vahter M. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ. Health Perspect., 115, 599-605 (2007).
39. Wood TC, Salavagionne OE, Mukherjee B, Wang L, Klumpp AF, Thomae BA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J. Biol. Chem., 281, 7364-7373 (2006).
40. Lindberg AL, Kumar R, Goessler W, Thirumaran R, Gurzau E, Koppova K, Rudnai P, Leonardi G, Fletcher T, Vahter M. Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ. Health Perspect., 115, 1081-1086 (2007).
41. Hernández A, Xamena N, Surrallés J, Sekaran C, Tokunaga H, Quinteros D, Creus A, Marcos R. Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat. Res., 637, 80-92 (2008).
42. Hernández A, Xamena N, Sekaran C, Tokunaga H, Sampayo-Reyes A, Quinteros D, Creus A, Marcos R. High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet. Genomics, 18, 349-355 (2008).
43. Agusa T, Iwata H, Fujihara J, Kunito T, Takeshita H, Minh TB, Trang PT, Viet PH, Tanabe S. Genetic polymorphisms in AS3MT and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol. Appl. Pharmacol., 236, 131-141 (2009).
44. Fujihara J, Kunito T, Agusa T, Yasuda T, Iida R, Fujii Y, Takeshita H. Population differences in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene polymorphism detected by using genotyping method. Toxicol. Appl. Pharmacol., 225, 251-254 (2007).
45. Fujihara J, Soejima M, Koda Y, Kunito T, Takeshita H. Asian specific low mutation frequencies of the M287T polymorphism in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Mutat. Res., 654, 158-161 (2008).
46. Sampayo-Reyes A, Hernández A, El-Yamani N, López-Campos C, Mayet-Machado E, Rincón-Castañeda CB, Limones-Aguilar ML, López-Campos JE, de León MB, González-Hernández S, Hinojosa-Garza D, Marcos R. Arsenic induces DNA damage in environmentally exposed Mexican children and adults. Influence of GSTO1 and AS3MT polymorphisms. Toxicol. Sci., 117, 63-71 (2010).
47. Engström K, Vahter M, Mlakar SJ, Concha G, Nermell B, Raqib R, Cardozo A, Broberg K. Polymorphisms in arsenic (+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ. Health Perspect., 119, 182-188 (2011).
48. Agusa T, Iwata H, Fujihara J, Kunito T, Takeshita H, Minh TB, Trang PT, Viet PH, Tanabe S. Genetic polymorphisms in glutathione S-transferase (GST) superfamily and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol. Appl. Pharmacol., 242, 352-362 (2010).
49. Gomez-Rubio P, Meza-Montenegro MM, Cantu-Soto E, Klimecki WT. Genetic association between intronic variants in AS3MT and arsenic methylation efficiency is focused on a large linkage disequilibrium cluster in chromosome 10. J. Appl. Toxicol., 30, 260-270 (2010).
50. Schläwicke Engström K, Nermell B, Concha G, Strömberg U, Vahter M, Broberg K. Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions. Mutat. Res., 667, 4-14 (2009).
51. Pi J, Yamauchi H, Sun G, Yoshida T, Aikawa H, Fujimoto W, Iso H, Cui R, Waalkes MP, Kumagai Y. Vascular dysfunction in patients with chronic arsenosis can be reversed by reduction of arsenic exposure. Environ. Health Perspect., 113, 339-341 (2005).
52. Sumi D, Fukushima K, Miyataka H, Himeno S. Alternative splicing variants of human arsenic (+3 oxidation state) methyltransferase. Biochem. Biophys. Res. Commun., 415, 48-53 (2011).